Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer
PRIMARY PROSTATE CANCER
Inclusion Criteria:
- Age ≤ 80 years
- Karnofsky index ≥ 80
- First prostate biopsy
- Presence of at least one of the following:
- Total PSA 10 ng/mL
- Total PSA 2.5-10 ng/mL with free-PSA <20% and/or PSA velocity 0.75 ng/mL/year
- Suspicious hypoechoic lesion at TRUS and/or suspicious finding at digital
rec¬tal examination
- Informed signed consent.
Exclusion Criteria:
- Impaired capacity to consent
- Coexistence of clinically-proven prostate cancer
- Neoadjuvant hormonal treatment (including 5-α reductase inhibitors)
- Contraindications to surgery
- Contraindications to MR Imaging (see below)
PROSTATE CANCER RELAPSE
Inclusion Criteria:
- Age ≤ 90 years
- Karnofsky index ≥ 80
- Previous treatment for prostate cancer
- No clinical recurrence based on standard work-up (abdominal / pelvic CT, MRI, and
bone scintigraphy)
- Biochemically proven relapse of prostate cancer (PSA > 0.2 ng/mL after prostatectomy,
nadir PSA+2 ng/mL (Phoenix definition) or ≤ 3 successive rising PSA levels (ASTRO
definition) after curative radiotherapy).
- Informed signed consent.
Exclusion Criteria:
- Coexistence of another clinically-proven cancer
- Contraindications to surgery or radiation therapy treatment